<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_SYSU-MEDICINE_Proof skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:SYSU-MEDICINE/Proof</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="container-fluid"><DIV class="navbar-header"><BUTTON type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#bs-example-navbar-collapse-1" aria-expanded="false"><SPAN class="sr-only">Toggle navigation</SPAN></BUTTON><A class="navbar-brand" href="https://2016.igem.org/Team:SYSU-MEDICINE">SYSU-MEDICINE</A></DIV><DIV class="collapse navbar-collapse" id="bs-example-navbar-collapse-1"><UL class="nav navbar-nav navbar-right"><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE">HOME</A></LI><LI class="dropdown active"><A href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">PROJECT</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Description">Description</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Results">Results</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Protocol">Protocol</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Notebook">Notebook</A></LI><LI class="dropdown third-level-menu"><A href="#" class="dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">For Judgement </A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Proof">Proof of Concept</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Demonstrate">Demonstrate</A></LI></UL><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">HUMAN PRACTICES</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Our_Story">Our Story</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Interview">Interview</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Ethics">Ethics</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Legislation">Legislation</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Products">Products</A></LI><LI class="dropdown third-level-menu"><A href="#" class="dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">For Judgement </A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/HP/Silver">Silver</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/HP/Gold">Gold</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Integrated_Practices">Integrated Practices</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Engagement">Engagement</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Modeling">MODELING</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">TEAM</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Team">Team</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Attributions">Attributions</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Collaborations">Collaborations</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">PARTS</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Parts">Parts</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Basic_Part">Basic Parts</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Composite_Part">Composite Parts</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Part_Collection">Part Collection</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Safety">SAFETY</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Judging">JUDGING</A></LI></DIV></DIV><DIV class="jumbotron"><DIV class="my-content"><H1 align="center">Proof of Concept</H1></DIV></DIV><DIV class="jumbotron" id="content"><DIV class="mynav"><OL><LI><A href="#Proof1">Expression</A></LI><LI><A href="#Proof1.1">Chemokine receptors</A></LI><LI><A href="#Proof1.2">Marking proteins</A></LI></OL><LI><A href="#Proof2">Function</A></LI><LI><A href="#Proof2.1">Elevated homing ability</A></LI><LI><A href="#Proof2.2">Locating</A></LI><LI><A href="#Proof3">Identification</A></LI><LI><A href="#Proof3.1">Phenotypes of MSCs</A></LI><LI><A href="#Proof3.2">Immunoregulatory function of MSCs</A></LI></DIV><DIV class="my-content"><P>
            MSCalvary (our modified MSCs) is a set of MSCs engineered with specific chemokine receptors and marking proteins. This summer vacation, we constructed the following devices which were testified both in vivo and in vitro.</P><TABLE><TBODY><TR><TD style="text-align: center"><SPAN class="note">
                        Figure 3.1.1
                        BBa_K1993009
                    </SPAN></TD><TD style="text-align: center"><SPAN class="note">
                        Figure 3.1.2
                        BBa_K1993005
                    </SPAN></TD></TR></TBODY></TABLE><P>With the purpose of increasing homing efficiency of MSCs and illustrating their distribution, we focused on three aspects of great importance for proof of our concept:
            -	Whether our devices express as expected;
            -	Whether our parts properly exert their function;
            -	Whether MSCs are negatively influenced by our system.</P><H2 id="Proof1">Expression</H2><P><B id="Proof1.1"><BIG>1 Chemokine receptors</BIG></B>
            To figure out whether our devices express properly, mRNA and protein levels of CXCR4 and CXCR5 of MSCs and our modified MSCs were semi-quantified and detected by qPCR and western blot, respectively. mRNA and protein levels of CXCR4 and CXCR5 all elevated in our modified MSCs.</P><TABLE><TBODY><TR><TD style="text-align: center;"><SPAN class="note">
                        Figure 3.2.1
                    </SPAN></TD><TD style="text-align: center;"><SPAN class="note">
                        Figure 3.2.2
                    </SPAN></TD><TD style="text-align: center;"><SPAN class="note">
                        Figure 3.2.3
                    </SPAN></TD></TR></TBODY></TABLE><P><B id="Proof1.2"><BIG>2 Marking proteins </BIG></B>
            -	eGFP
            As for expression of eGFP, transfected 293T cells (Figure 3.2.4A: EF-1α-CXCR5-IRES-eGFP; Figure 3.2.4B: EF-1α-CXCR4-T2A-luciferase-IRES-eGFP) and MSCs (Figure 3.2.5A: EF-1α-CXCR5-IRES-eGFP; Figure 3.2.5B: EF-1α-CXCR4-T2A-luciferase-IRES-eGFP) were observed under fluorescent microscope. As a result, eGFP were expressed.</P><TABLE><TBODY><TR><TD style="text-align: center;width:430px"><SPAN class="note">
                        Figure 3.2.4
                    </SPAN></TD><TD style="text-align: center;width:430px"><SPAN class="note">
                        Figure 3.2.5
                    </SPAN></TD></TR></TBODY></TABLE><P>-	Luciferase
            Under IVIS Spectrum, MSCs with degraded luciferin could be clearly observed.<SPAN style="text-align: center;" class="note">
                Figure 3.2.6</SPAN></P><H2 id="Proof2">Function</H2><P><B id="Proof2.1"><BIG>1 Elevated homing ability</BIG></B>
            In order to verify whether engineered MSCs successfully acquired elevated chemotaxis, in vivo and in vitro experiments were conducted.
            -	In vitro verification
            Chemotaxis of engineered MSCs were examined against CXCL12 and CXCL13 respectively. Results were reported as number of cells migrated. Chemotaxis capacity of our engineered MSCs all improved.</P><TABLE><TBODY><TR><TD style="text-align: center;"><SPAN class="note">
                        Figure 3.3.1
                    </SPAN></TD><TD style="text-align: center;"><SPAN class="note">
                        Figure 3.3.2
                    </SPAN></TD></TR></TBODY></TABLE><SPAN style="text-align: center;" class="note">
                    Figure 3.3.3
                </SPAN><P>
            -	In vivo verification
            · Under IVIS Spectrum, MSCs<SUP>CXCR4</SUP> exhibited enhanced capacities for targeted migration to the bowels in IBD model.<SPAN style="text-align: center;" class="note">
                Figure 3.3.4
            </SPAN>
            · The inflamed ears were collected from each group and subjected to in situ immunofluorescence staining. Our results revealed that MSCs<SUP>CXCR5</SUP> exhibited enhanced capacities for targeted migration to the ears in DTH model.<SPAN style="text-align: center;" class="note">
                Figure 3.3.5
            </SPAN><B id="Proof2.2"><BIG>2 Locating</BIG></B>
            · Under IVIS Spectrum, MSCs<SUP>CXCR4</SUP> could be detected and located in IBD mice.<SPAN style="text-align: center;" class="note">
                Figure 3.3.6</SPAN>
            · The inflamed ears were collected from each group, subjected to in situ immunofluorescence staining and observed under fluorescence microscope. Our results revealed MSCs<SUP>CXCR5</SUP> could be located in the inflamed ears of DTH mice.<SPAN style="text-align: center;" class="note">
                Figure 3.3.7</SPAN></P><H2 id="Proof3">Identification</H2><P>Our modified MSCs still remained their own characteristics, including phenotypes and Immunoregulatory function.<B id="Proof3.1"><BIG>1 Phenotypes of MSCs</BIG></B>
            Our modified MSCs were still positive for CD105, CD90, CD29 and CD73 and negative for CD34 (Figure 3.4.1 A-E), and were able to differentiate to osteoblasts, adipocytes, and chondroblasts under standard in vitro differentiating conditions (Figure 3.4.2 F-K). (Meet the standard of International Society for Cellular Therapy (ISCT))</P><TABLE><TBODY><TR><TD style="text-align: center;"><SPAN class="note">
                        Figure 3.4.1
                    </SPAN></TD><TD style="text-align: center;"><SPAN class="note">
                        Figure 3.4.2
                    </SPAN></TD></TR></TBODY></TABLE><P><B id="Proof3.2"><BIG>2 Immunoregulatory function of MSCs</BIG></B>
            For MSCs<SUP>CXCR4</SUP>
            · Colon sampling for quantitative PCR analysis. Comparing with TNBS+MSC group, levels of the anti-inflammatory cytokine (IL-10) elevated in TNBS+MSCs<SUP>CXCR4</SUP> group while pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) levels decreased in TNBS+ MSCs<SUP>CXCR4</SUP> group. In a word, MSCs<SUP>CXCR4</SUP> have greater immunoregulatory function.</P><P align="center"><TABLE><TBODY><TR><TD style="text-align: center;"><SPAN class="note">
                     Figure 3.4.3
                    </SPAN></TD><TD style="text-align: center;"><SPAN class="note">
                 Figure 3.4.4
                </SPAN></TD></TR><TR><TD style="text-align: center;"><SPAN class="note">
                        Figure 3.4.5
                    </SPAN></TD><TD style="text-align: center;"><SPAN class="note">
                        Figure 3.4.6
                    </SPAN></TD></TR></TBODY></TABLE></P><P>
            · After injecting with MSCs<SUP>CXCR4</SUP>, survival rate, body weight, length of colon and DAI score of IBD mice were improved significantly comparing to TNBS+MSC group and TNBS+saline group. In a word, MSCs<SUP>CXCR4</SUP> have greater immunoregulatory function.</P><P align="center"><TABLE><TBODY><TR><TD style="text-align: center;"><SPAN class="note">
          Figure 3.4.7
      </SPAN></TD><TD style="text-align: center;"><SPAN class="note">
          Figure 3.4.8
      </SPAN></TD></TR><TR><TD style="text-align: center;"><SPAN class="note">
                        Figure 3.4.9
                    </SPAN></TD><TD style="text-align: center;"><SPAN class="note">
                        Figure 3.4.10
                    </SPAN></TD></TR></TBODY></TABLE></P><P>
            · Photographs of hematoxylin/eosin-stained colon cross-sections 2 days after injecting MSCs. MSCs<SUP>CXCR4</SUP> displayed better treatment efficacy than TNBS+MSC group and TNBS+saline group, characterized by their abilities to decrease leukocyte infiltration. In a word, MSCs<SUP>CXCR4</SUP> have greater immunoregulatory function.<SPAN style="text-align: center;" class="note">
                Figure 3.4.11</SPAN>
            For MSCs<SUP>CXCR5</SUP>
            · Ear sampling for quantitative PCR analysis. Comparing with DTH+MSCs group, levels of the anti-inflammatory cytokines (IL-10), elevated in DTH+MSCs<SUP>CXCR5</SUP> group, while levels of pro-inflammatory cytokines (IL-4, TNF-α, IFN-γ, IL-6 and IL-17) decreased in DTH+MSCs<SUP>CXCR5</SUP> group. In a word, MSCs<SUP>CXCR5</SUP> have greater immunoregulatory function.<SPAN style="text-align: center;" class="note">
                Figure 3.4.12</SPAN>
            · After injection, MSCs<SUP>CXCR5</SUP> displayed better treatment efficacy than DTH+MSCs<SUP>eGFP</SUP> group, characterized by their abilities to decrease ear thickness and leukocyte infiltration. MSCs<SUP>CXCR5</SUP> significantly attenuated DTH as early as 24 hours post-injection, and had even greater effects at 48 hours post-injection. In a word, MSCs<SUP>CXCR5</SUP> have greater immunoregulatory function.<SPAN style="text-align: center;" class="note">
                Figure 3.4.13</SPAN><SPAN style="text-align: center;" class="note">
                Figure 3.4.14</SPAN></P></DIV></DIV><DIV class="jumbotron" id="jumbo-footer"><DIV class="footer-container"><DIV class="title">
            Contact us
        </DIV><DIV class="contact"><UL class="float-contact"><LI><A href="http://weibo.com/u/5999650333">
                        iGEMxSYSU-MEDICINE
                    </A></LI><LI><A href="https://www.facebook.com/IGEM-SYSU-Medicine">
                        IGEM SYSU-Medicine
                    </A></LI><LI><A href="#">
                        SYSU_MEDICINE@163.com
             </A></LI></UL><UL class="float-contact"><LI><A href="#" data-toggle="modal" data-target="#wechatModal">
                        SYSU-MEDICINE
                    </A></LI><LI><A href="https://twitter.com/IgemSysu">
                        iGEM SYSU-MEDICINE
                    </A></LI></UL></DIV><DIV class="copyright"><DIV class="text">© 2016 SYSU-MEDICINE. All Rights Reserved.
            </DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>